JCO global oncology · 2026
Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cayol Federico, Macharashvili Iván, Barochiner Jessica, Dominguez María Pía, Menna Emiliano, Perez Mesa Pablo Jose, Pandolfi Julieta, Carranza Omar, Sanchez Rodrigo, Marchioni Andrea, Gueron Geraldine, Pena Luz, Cerini Matias, Cutuli Hernan, Rivello Hernan Garcia, Taetti Gonzalo, Camacho Augusto Ferreyra
Аннотация
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited.
MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT).
RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification.
CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.
MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT).
RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification.
CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.